Forty Seven Inc. is a clinical-stage immuno-oncology company that is developing therapies licensed from Stanford University targeting cancer immune evasion pathways.
Forty Seven, Inc.
[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”FTSV” api=”yf” style=”font-size: 15px”]
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/forty-seven-inc-” connections=”true” suffix=””]
In Feb 2016, Stanford University granted Forty Seven, an exclusive, worldwide rights to a patent portfolio covering the antibody Hu5F9-G4 and several other novel immune checkpoint inhibitors and cancer-specific antibodies.
In Feb 2016, Forty Seven Inc. raised the first half of a committed $75 Mn Series A financing round led by Lightspeed Venture Partners and Sutter Hill Ventures with participation from Clarus Ventures and GV (formerly Google Ventures).